Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 Receivables Turnover is 0.97 as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 843 Biotechnology companies, StemCyte International ranks worse than 71.77% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. StemCyte International's Revenue for the
three
months ended in Mar. 2026 was NT$87.8 Mil. StemCyte International's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$91.0 Mil.
Hence, StemCyte International's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.97.
StemCyte International (TPE:4178) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
StemCyte International Receivables Turnover Related Terms
StemCyte International Receivables Turnover Historical Data
* Premium members only.
The historical data trend for StemCyte International's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, StemCyte International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where StemCyte International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCyte International (TPE:4178) has a Receivables Turnover of 0.97 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on StemCyte International and its competitors. According to the industry distribution chart, StemCyte International ranks #605 out of 843 companies in the Biotechnology industry, placing it in the top 71.8%.
Is StemCyte International's Receivables Turnover too high?
StemCyte International's current Receivables Turnover is 0.97. The Biotechnology industry median Receivables Turnover is 5.26. StemCyte International's value of 0.97 is 81.6% below this industry median. Based on the distribution chart, StemCyte International ranks #605 out of 843 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #605 out of 843 companies for Receivables Turnover. This places StemCyte International in the lower half of its industry. The industry median Receivables Turnover is 5.26. StemCyte International's value of 0.97 is 81.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.26, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current Receivables Turnover of 0.97 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on StemCyte International and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current Receivables Turnover is 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Receivables Turnover of 0.97. The current Receivables Turnover is 0.97 and 81.6% below the Biotechnology industry median of 5.26. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Receivables Turnover is 0.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
